Bendamustine in Combination With Ofatumumab, Carboplatin, Etoposide for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin, Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Leukemia and Lymphoma 2020 Nov 04;[EPub Ahead of Print], J Pan, S Ghimire, SO Alpdogan, A Chapman, M Carabasi, M DiMeglio, J Gong, U Martinez-Outschoorn, L Rose, M Ramirez, JL Wagner, M Weiss, N Flomenberg, B Pro, P Porcu, J Filicko-OHara, S GaballaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.